Kiromic Biopharma (KRBPQ) AI Stock Analysis

• Market Cap: $157.00
• Dividend Yield: N/A
• Average Volume (3M): 3.09K
• Price to Earnings (P/E): ―
• Beta (1Y): -3.13
• Revenue Growth: N/A
• EPS Growth: -4.26%
• Country: US
• Employees: 44
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): N/A
• Shares Outstanding: 1,570,919
• 10 Day Avg. Volume: 3,734
• 30 Day Avg. Volume: 3,091
• PEG Ratio: N/A
• Price to Book (P/B): 0.00
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: 0.00
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

No summary available

Positive Factors

Innovative Technology Platforms

Kiromic Biopharma's focus on proprietary technology platforms in immuno-oncology positions it to potentially revolutionize cancer treatment, offering long-term competitive advantages in the biotechnology sector.

Negative Factors

Increasing Losses

Rising losses reflect high R&D expenses without offsetting revenue, challenging Kiromic's financial sustainability and necessitating strategic pivots to achieve profitability.

Kiromic Biopharma Business Overview & Revenue Model

Company Description

Kiromic BioPharma, Inc., an artificial intelligence driven allogeneic cell therapy company, engages in developing the multi-indication allogeneic T cell therapies that exploits the natural potency of the Gamma Delta T cell to target solid tumors. ...

Read more

Kiromic BioPharma, Inc., an artificial intelligence driven allogeneic cell therapy company, engages in developing the multi-indication allogeneic T cell therapies that exploits the natural potency of the Gamma Delta T cell to target solid tumors. ...

How the Company Makes Money

Kiromic Biopharma makes money primarily through the development and commercialization of its immuno-oncology products. The company generates revenue by licensing its technology platforms and collaborating with pharmaceutical companies to develop n...

Read more

Kiromic Biopharma makes money primarily through the development and commercialization of its immuno-oncology products. The company generates revenue by licensing its technology platforms and collaborating with pharmaceutical companies to develop n...

Kiromic Biopharma Financial Statement Overview

Breakdown
Income Statement
Total Revenue
Gross Profit
EBITDA
Net Income
Balance Sheet
Total Assets
Cash, Cash Equivalents and Short-Term Investments
Total Debt
Total Liabilities
Stockholders Equity
Cash Flow
Free Cash Flow
Operating Cash Flow
Investing Cash Flow
Financing Cash Flow

Kiromic Biopharma Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.04
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For KRBPQ, the sentiment is Negative. The current price of 0.04 is below the 20-day moving average (MA) of 0.04, above the 50-day MA of 0.04, and below the 200-day MA of 0.46, indicating a neutral trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 44.56 is Neutral, neither overbought nor oversold. The STOCH value of 71.43 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for KRBPQ.

Kiromic Biopharma Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
KRBPQ	―	$157.00	>-0.01	―	―	―	-4.26%
SCNI	44 Neutral	$2.01M	-0.20	―	―	178.82%	-4121.10%
DRMA	44 Neutral	$4.91M	-0.28	-203.36%	―	―	90.53%
AZTR	43 Neutral	$3.68M	-0.12	-215.04%	―	-100.00%	93.82%